Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study

Trial Profile

Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Olaparib (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PARADIGM
  • Most Recent Events

    • 04 Sep 2015 Accrual to date is 1% as reported by the United Kingdom Clinical Research Network record.
    • 13 Aug 2015 Accrual to date is 0% as reported by United Kingdom Clinical Research Network record.
    • 10 Jul 2014 According to the ISRCTN record, trial status is changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top